Abstract:3103 Background: Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disease characterized by elevated RAS-mitogen activated protein kinase (MAPK) signaling that causes tumors to grow along the nerves. There is currently no medical cure for adult patients (pts). Plexiform neurofibromas (PN) is present in 20-50% of NF1 pts and may cause serious complications. FCN-159 is a highly potent anti-tumorigenic agent that functions via selective inhibition of MEK1/2. This study assessed the safety and efficacy of FCN-159 in adult NF1 pts with PN. Methods: This was a multi-center, open-label, single-arm phase 1 dose-escalation (data have been published in ASCO 2022, abstract no. 3011) and phase 2 dose-expansion study. Participants with NF1-related PN that was not completely resectable or not suitable for surgery were enrolled in the study to receive FCN-159 monotherapy continuously on a 28-day cycles. Herein, we report the safety and clinical efficacy of adult participants in both phase 1 and phase 2. Results: As of November 21, 2022, 82 pts were enrolled, including 19 pts in phase 1 and 63 pts in phase 2. The median follow-up was 10.2 months (range 9.4-11.0 months) at the data cut-off. All pts received more than one dose of FCN-159 and 78 had at least one tumor assessment based on REiNS critiera. A total of 26 (33%) pts had achieved partial response (PR) as best response, 51 (65%) pts had stable disease (SD), and only one pt was not evaluable for not meeting the minimum SD requirement of at least 16 weeks. The overall response rate (ORR) was 31.7% (95% CI: 21.9-42.9%). After 6-8 cycles of treatment, 68.2% (15/22) of pts with definite tumor pain (NRS-11 score≥2 points) at baseline had a decrease in pain intensity of at least 2 points at C7/C9 assessment. Pain scores decreased by an average of 2.7 points across all 22 pts. A total of 82 (100%) pts experienced treatment emergent adverse events (TEAEs). The most common TEAEs (≥ 20%) included folliculitis (69.5%), mouth ulcer (47.6%), diarrhea (41.5%), paronychia (41.5%), alopecia (32.9%), elevated lactate dehydrogenase (30.5%), elevated alkaline phosphatase (29.3%), tricuspid insufficiency (26.8%), and mitral insufficiency (26.8%). The most common grade ≥3 TEAEs were folliculitis (25.6%), paronychia (4.9%). There were no grade ≥ 4 treatment-related adverse events. One pt (1.2%) experienced a serious adverse event (duodenal ulcer) considered related to the study drug. 9.8% reported TEAEs leading to dose reductions, and 12.2% reported TEAEs leading to discontinuation. No death occurred during the study. Conclusions: Overall, FCN-159 has a manageable safety profile and demonstrated evidence of anti-tumor activity in the adult population with NF1-related PN. These promising findings warrant further investigation with long-time follow-up. Clinical trial information: NCT04954001 .

Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency

Pharmacological and Genomic Profiling of Neurofibromatosis Type 1 Plexiform Neurofibroma-Derived Schwann Cells

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors

Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma

A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.

Abstract 3106: Integrated in vitro and machine learning approaches for targeted drug screening in gliomas with concurrent NF1 and ATRX loss

Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Screening in NF2-associated Schwannoma.

Preclinical Therapeutic Efficacy of a Novel Pharmacologic Inducer of Apoptosis in Malignant Peripheral Nerve Sheath Tumors.

Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing

Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis

DDDR-18. SINGLE-CELL FUNCTIONAL GENOMIC ANALYSIS OF PHARMACOLOGIC RESPONSES IN NF1 MUTANT GLIOBLASTOMA REVEALS DISTINCT MECHANISMS OF ACTION FOR MEK AND SHP2 INHIBITION

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of FCN-159 in Adults with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas.

CTNI-46. WINDOW-OF-OPPORTUNITY TRIAL OF ULIXERTINIB FOR MAPK-ACTIVATED LOWER GRADE GLIOMAS IN ADULTS

Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular Signal–Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I

A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.

Efficacy and Safety of FCN-159, a MEK1/2 Inhibitor in Pediatric Participants with Neurofibromatosis Type 1: Results from a Phase 2 Trial.

Multiplatform molecular profiling and functional genomic screens identify prognostic signatures and mechanisms underlying MEK inhibitor response in somatic NF1 mutant glioblastoma

Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas

Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial

Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression